Loading
Life sciences · Journal article
Journal of Geriatric Oncology · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Medicare Advantage (MA) plans have grown in popularity and currently cover over half of all beneficiaries [1]. Although MA plans offer supplemental benefits and out-of-pocket maximums [2], they also employ numerous strategies to control health care spending. Specifically, MA plans often restrict care to in-network providers and require utilization management (e.g., prior authorization, step therapy) for nearly all self- and clinician-administered anticancer therapies [1]. Evidence suggests that MA enrollment is associated with a low likelihood of starting any or high-cost systemic therapies among beneficiaries with advanced lung cancer [1,3], raising concerns that cost-containment strategies could limit access to guideline-recommended care.